

# Crosstalk between oral and general health status in e-smokers

Marco Tatullo, PhD<sup>a,\*</sup>, Stefano Gentile, PhD<sup>b</sup>, Francesco Paduano, PhD<sup>a</sup>, Luigi Santacroce, MD<sup>c</sup>, Massimo Marrelli, MD<sup>d</sup>

## Abstract

Electronic cigarette (e-cigarette) simulates the act of tobacco smoking by vaporizing a mixture of propylene glycol, nicotine, and flavoring agents. e-cigarette has been proposed as a product able to aid to stop smoking. The aim of the study is to verify the clinical variations of periodontal health induced by e-cigarettes use and, moreover, to investigate about the awareness of the e-smokers about their health variations and about their hypothetical need to turn back to smoke combustible cigarettes.

This clinical observational pilot study involved 110 out of 350 smokers, who switched to e-cigarette. Patients were subjected to oral examinations. A questionnaire to self-assess the variations of some parameters of general health, and to self-assess the need to smoke combustible cigarettes, was distributed to such subjects involved in the study.

At the end of the study, we registered a progressive improvement in the periodontal indexes, as well as in the general health perception. Finally, many patients reported an interesting reduction in the need to smoke.

In the light of this pilot study, the e-cigarette can be considered as a valuable alternative to tobacco cigarettes, but with a positive impact on periodontal and general health status.

**Abbreviations:** BI = bleeding index, CO = carbon monoxide, e-cigarette = electronic cigarette, e-smoker = electronic smoker, PBI = papillary bleeding index, PI = plaque index.

**Keywords:** nicotine, prevention, tobacco

## 1. Introduction

Tobacco smoking is the largest preventable cause of death in the world today<sup>[1]</sup>; the estimated overall prevalence of active smokers in high-income countries, according to the World Mental Health Surveys, ranges between 20% and 30% of the population, against the 5% to 35% observed among the middle-income and low-income countries<sup>[2]</sup>; thus, making the cigarette smoking one of the major worldwide public health issues.<sup>[3]</sup> Although it is well known that cigarette smoking is a risk factor for cardiovascular diseases,<sup>[4]</sup> pulmonary diseases, cancer,<sup>[5]</sup> and other systemic pathologies, the area of human body directly exposed to tobacco smoke effects is the oral cavity.<sup>[6–10]</sup> Neoplastic and preneoplastic conditions take a particular attention among oral diseases induced by tobacco smoking, because of the importance that early diagnosis can have with such clinical pictures.<sup>[11]</sup> Cigarettes

smoking is also one of the most important known cofactor in the development of oral leukoplakia,<sup>[12]</sup> palatal leukokeratosis and melanosis,<sup>[13]</sup> and of the modifications of the oral microenvironment which can lead to several opportunistic pathologies, such as oral candidiasis and hairy tongue.<sup>[14]</sup> Furthermore, tobacco smoking represents a high risk factor for periodontal diseases,<sup>[15]</sup> enhancing the loss of gingival attachment,<sup>[16]</sup> and the increase of gingival regression,<sup>[17]</sup> with the final result of a severe progression of periodontal inflammation.

As reported in literature, wound healing after periodontal scaling was significantly altered in smokers,<sup>[18]</sup> with an increased risk of dental implant failure.<sup>[19]</sup>

Quit smoking entails a clear reduction of the smoke-related diseases,<sup>[20]</sup> and a decreased exposure to the risk to develop oral cancer<sup>[21]</sup> and periodontal diseases.<sup>[13]</sup> A strong addiction to nicotine can make it very hard to stop smoking; in this case, a therapy with nicotine substitutes, such as the transdermal patches,<sup>[22]</sup> can help to reduce the consumption of tobacco cigarettes.

A new alternative therapy is the electronic cigarette, also known as e-cigarette.<sup>[23]</sup> This device simulates the act of tobacco smoking, by vaporizing a mixture of propylene glycol, nicotine, and flavoring agents.<sup>[24,25]</sup>

E-cigarette companies propose their product as a smoking cessation aid; however, some clinical studies failed to demonstrate a complete stop of the consumption of combustible cigarettes by the electronic smokers (e-smokers)<sup>[26]</sup> and failed to demonstrate a better efficacy of e-cigarettes with respect to other nicotine substitutes.<sup>[27]</sup>

Our study was aimed to assess the variations of oral and general health status in a population of randomized smokers who switched to e-cigarette. Particular attention has been paid to the periodontal health status, by analyzing the plaque index (PI) and

Editor: Ediriweera Desapriya.

The authors have no funding and conflicts of interest to disclose.

<sup>a</sup> Tecnologica Research Institute, <sup>b</sup> Marrelli Hospital, Clinical Research Area, Crotone, <sup>c</sup> Department of JSGEM, University of Bari, Bari, <sup>d</sup> Calabro dental Clinic, Crotone, Italy.

\* Correspondence: Marco Tatullo, Tecnologica Research Institute, St. E. Fermi, Crotone 8890, Italy (e-mail: marco.tatullo@tecnologicarsi.com).

Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.

Medicine (2016) 95:49(e5589)

Received: 23 July 2016 / Received in final form: 11 November 2016 / Accepted: 14 November 2016

<http://dx.doi.org/10.1097/MD.00000000000005589>

periodontal bleeding index (BI). Furthermore, we provided to the enrolled patients a self-assessment questionnaire to evaluate the awareness of patients involved in this study about the changes in their general health status, induced by the switching from combustible cigarette to e-cigarette.

## 2. Materials and methods

This clinical observational study was carried out at the Unit of Periodontology and Oral Hygiene of Calabrodental Clinic (Crotone, Italy). The Ethics Committee specifically required by Calabrodental approved this study and the related procedures (Prot. July-2012/Res005). Written informed consent was obtained from the patients by filling in a specific form. The study followed the "Ethical principles for medical research involving human subjects" of the Helsinki Declaration. The study was conducted in accordance with Italian laws and regulations. The study complies with the STROBE Guidelines.

### 2.1. Patients selection

This study was conducted for 120 days on each patient. Clinical examinations were performed at 3 different check-points:  $T_0$  (baseline),  $T_1$  (after 60 day), and  $T_2$  (after 120 days).

A total of 350 e-smokers were randomly recruited for this study. The 1st selection was performed by choosing those subjects which started to use e-cigarette approximately from  $4 \pm 1$  months, before the start of the study. We also asked if they would like to stop smoking and if they would like to participate to a clinical study aimed to assess their oral health. Exclusion criteria were pregnancy and the presence of any clinical condition requiring any premedication (cancer, respiratory, cardiovascular, and/or any severe oral disease). Smokers were divided into 2 groups, according to the number of years of smoking by each of them: group 1 (less than 10 years of tobacco smoking), group 2 (more than 10 years of tobacco smoking). All subjects were asked to abstain from tobacco cigarettes for the entire duration of the study; they were asked to report on a personal diary, properly created and provided to patients by the Calabrodental teamwork, if they were able to fulfill the indications suggested by our researchers, or, conversely, if they smoked during this specific period, and how many tobacco cigarettes they smoked. To avoid the possibility that the outcomes of this study could be influenced by the Hawthorne effect,<sup>[28]</sup> patients were asked not to change their oral hygiene habits during the observational time.

Only 110 e-smokers (89 men and 21 women, average age  $31 \pm 9$ ; group 1=60 subjects, group 2=50 subjects) out of 350 were included in the final stage of the study, as shown in Fig. 1.

### 2.2. Nicotine consumption

All the recruited patients, who switched to the e-cigarettes, reported that they have previously smoked only combustible cigarettes with high amount of nicotine (among 0.8–1 mg per cigarette).

All patients included in our study stated that they use e-cigarettes with an average content of 0.25 mL of liquid containing a total amount of nicotine equivalent to 18 mg: each cycle of use of the e-cigarette contains on average 4.5 mg of nicotine, although the calculation should not consider the dispersed nicotine part, equal to about half of the basic content. The subjects enrolled in the study said they had smoked in the past an average of 20 cigarettes a day, absorbing an average of 16 mg of nicotine per

day. With the e-cigarette, if subject smokes the same number of cigarettes in a day it would be absorbed approximately 7 mg of nicotine.

### 2.3. Intraoral examinations

The oral cavity was divided in 4 areas: upper right and upper left jaw, lower right and lower left jaw. Each patient underwent an accurate oral examination to investigate the following parameters: PI (according to Silness and Loe; 1964), BI (according to Carter and Barnes; 1974), and papillary bleeding index (PBI; according to Muhleman; 1977). All the measurements were taken by using a periodontal probe that measures to one tenth millimeter, according to the commonly used standardized techniques, and with the aid of the digital radiology and of the software for image analysis.

Mean ( $\pm$ standard deviation) values for PI and PBI were calculated and graphically represented on a chart. In order to avoid potential bias, all the procedures were standardized, and the operators who performed the measurements were not fully aware about the final aim of the study.

### 2.4. Self-assessment questionnaire

At the end of the observational period, patients were asked to answer a self-assessment questionnaire of 5 entries: general health status; smell perception; taste perception; frequency of respiratory diseases; and need to smoke. All entries were associated to a rating scale. The answers were properly archived and analyzed.

### 2.5. Smoke Check-meter assay


To ensure the reliability of this research, we asked to all the involved patients to sign at the end of the study a declaration assessing their strict adherence to the indications of the physicians, particularly regarding the stop smoking of combustible cigarette. Moreover, we randomly selected a sample of 20% among the enrolled patients (22 patients, 18 men and 4 women) and we asked them to undergo to a breath-test with the Smoke Check-meter assay. With this test, we analyzed the exhaled breath carbon monoxide (CO): this test allows to know whether patient has smoked combustible cigarettes in the last period or not; we asked to these patients, randomly selected by a casual numbers generator, to carry out Smoke Check-meter test at  $T_0$ ,  $T_1$ , and  $T_2$ .

The Smoke Check meter is a technology used for the analysis of exhaled breath CO. Smoke Check meter detects the CO eventually present in exhaled breath in parts per million (ppm) and it is used to check the smokers aiming to stop smoking: the CO values obtained from this examination are particularly accurate in detecting not smoking for at least 24 hours.

## 3. Results

### 3.1. Evaluation of general and oral health status at $T_0$

All subjects came from the macroregion of the Southern Italy; they belonged to different social classes, and they had an average age of  $31 \pm 9$  years. Patients involved in this study were clinically examined to assess their general health status at  $T_0$ . No respiratory and cardiovascular diseases were reported by any subject of both groups. No missing data were reported for any of the subjects involved at the end of the study. Dental decay of



**Figure 1.** Flowchart of participation to the study. Only 110 smokers (89 men and 21 women, average age  $31 \pm 9$ ; group 1 = 60 subjects, group 2 = 50 subjects) out of the initially recruited 350 were included in the final stage of the study. The flowchart describes, for each timepoint, the number of patients excluded or withdrawn from the study.

several degrees and nicotine induced dental pigmentation have been reported in 45 subjects of group 1 and in all subjects of group 2.

### 3.2. Plaque index at T<sub>0</sub>, T<sub>1</sub>, and T<sub>2</sub>

At T<sub>0</sub> 85% of subjects of group 1 showed PI scores equal to 1; only in 15 subjects it was found PI score equal to 0 (no plaque) (Table 1). In group 2, 73% of subjects were found with a PI score equal to 2, while PI scores of 1 or 3 were assigned to 12% and 15% of the remaining subjects, respectively (Table 1).

At T<sub>1</sub> slight changes started to be appreciable. In group 1 the percentage of patients with PI score of 0 increased to 54%, while

a thin plaque film persisted in the rest of the subjects of this group (PI score equal to 1) (Table 1). A more noticeable improvement (PI score equal to 0 or 1) was observed in 81% of the subjects, with the remaining percentage still showing a PI score of 2 (Table 1).

The final observation at T<sub>2</sub> revealed an overall improvement of the PI among nearly the totality of subjects of group 1 (PI score equal to 0 in 92% of subjects) (Table 1). Similarly, a remarkable plaque regression was observed in the 87% of subjects of group 2 (Table 1).

We calculated the mean value of PI scores in the 2 groups to show the variations of plaque accumulation on a chart. In group 1, PI decreased from a mean value of  $0.9 \pm 0.3$  (T<sub>0</sub>) to 0 (T<sub>2</sub>);

**Table 1****PI, BI, and PBI distribution in the 2 groups.**

PI	BI				PBI			
Group 1 (% value)	0	1	2	3	Yes	No	0	1
T <sub>0</sub>	15	85	—	—	61	39	66	34
T <sub>1</sub>	54	46	—	—	55	45	84	16
T <sub>2</sub>	92	8	—	—	8	92	98	2
Group 2 (% value)	0	1	2	3	Yes	No	0	1
T <sub>0</sub>	—	12	73	15	65	35	60	5
T <sub>1</sub>	41	40	16	3	48	52	76	24
T <sub>2</sub>	87	13	—	—	2	98	100	—

BI=bleeding index, PBI=papillary bleeding index, PI=plaque index.


however, the decrease was more evident in group 2 with PI score going from  $2.13 \pm 0.5$  (T<sub>0</sub>) to  $0.25 \pm 0.45$  (T<sub>2</sub>) (Fig. 2).

### 3.3. Bleeding index at T<sub>0</sub>, T<sub>1</sub>, and T<sub>2</sub>


At T<sub>0</sub> many subjects of group 1 showed a gingival bleeding response after probe stimulation. Similarly, a bleeding response was observed in the most of subjects of group 2 (Table 1).

An improving trend was recorded at T<sub>1</sub> for both groups: more precisely, in almost the half of the subjects of group 1 the presence of bleeding was clinically reduced while, in group 2, gingival bleeding was persisting in slightly less than half of the subjects (Table 1).

At T<sub>2</sub> a noteworthy improvement of the periodontal status, with no bleeding reaction after stimulation with a probe, was



**Figure 2.** Comparison of PI and PBI values from T<sub>0</sub> to T<sub>2</sub>. Group 1 (blue line) shows a PI that remains rather constant between T<sub>0</sub> and T<sub>1</sub>, instead, group 2 (red line) shows a PI that tends to decrease homogeneously from T<sub>0</sub> to T<sub>2</sub>. On the other hand, the PBI shows a trend rather comparable between the 2 groups, of course, starting from different values at baseline. PI and PBI values are expressed as mean  $\pm$  standard deviation. Clinical cases represent the appearance of the clinical conditions at different time points: (A–C) show the variation of PI from T<sub>0</sub> to T<sub>2</sub>; (D, E) show the variation of PBI from T<sub>0</sub> to T<sub>2</sub>. PBI=papillary bleeding index, PI=plaque index.



**Figure 3.** Self-awareness questionnaire used in the study. This questionnaire was filled by patients enrolled and maintained into the study protocol until its conclusion. Five questions were reported on questionnaire: they ranged from the general health status to the smell perception, the taste perception, the respiratory clinical conditions, and up to the need to return to smoke the classic cigarettes. Each indicator was assessed after having analyzed the replies collected by the patients: the reported data were based on the subjective evaluation of the parameter investigated.

observed in over the 90% of subjects of both groups (92% for group 1 and 98% for group 2, respectively) (Table 1).

#### 3.4. Papillary bleeding index at $T_0$ , $T_1$ , and $T_2$

No papillary bleeding was found in the 66% of subjects of group 1 at  $T_0$  (PBI score equal to 0), just a mild papillary bleeding was instead observed only in the 34% of subjects (PBI score equal to 1). On the other hand, many subjects of group 2 showed no papillary bleeding (PBI score equal to 0), only in the 35% of the subjects a sever papillary bleeding (PBI score of 2 and 3) was still observed (Table 1).

Absence of papillary bleeding was reported in the 84% of subjects of group 1 (PBI score equal to 0) at  $T_1$ , nonetheless, a slight papillary bleeding persisted in the 16% of the subjects (PBI score of 1). In group 2, we observed a similar trend with an equally conspicuous percentage (76%) of subjects who showed no papillary bleeding (PBI score of 1).

This improvement was confirmed by the analysis of the variation of PBI mean values. From the analysis of the mean values it emerged that in group 1 PBI reduced from  $0.4 \pm 0.49$  at

$T_0$  to 0 at  $T_2$  (Fig. 2), while in group 2 PBI switched from  $1.25 \pm 1.34$  at  $T_0$  to 0 at  $T_2$  (Fig. 2), showing a marked positive effect in this group.

#### 3.5. Self-assessment questionnaire

At the end of this observational clinical study, we analyzed the answers given by all the subjects to the self-assessment questionnaire. Subjects were asked to indicate on a rating scale (Fig. 3), the improvements they thought to have achieved about their general health status, about their smell and taste perception, about the frequency of respiratory diseases, and finally, about the need to turn back to smoke combustible cigarettes.

Almost 71% of the subjects felt an amelioration of their general health status (55 out of 110 marked “better” on the rating scale, while 23 out of 110 marked “quite better”) at the end of the observational study. Less than 1/3 of all subjects (30 out of 110) did not feel any clear change, neither positive nor negative, of their general health status, while only 2 subjects indicated a worsening of the general health status (Fig. 3A).

Unanimous positive response was reported for the self-perception of smell and taste variations: none of the subjects reported a worsening. More in detail, over 80% of subjects clearly indicated a positive variation in both smell and taste perception (Fig. 3B and C); the other subjects did not feel substantial changes to disclose (Fig. 3B and C).

Similarly, a large percentage (78%) of subjects interestingly reported a reduction of the frequency of respiratory diseases (Fig. 3D). The final entry of the questionnaire, about the perceived need to smoke, revealed that 96 out of 110 subjects felt only a moderate or absent need to smoke; the other 14 patients revealed to perceive the need to turn back to combustible cigarettes (Fig. 3E).

No patient reported to have occasionally smoked the combustible cigarettes, during the study: at the end of the study, the recruited subjects signed a declaration, where they ensured the complete agreement to the recommendations of the clinicians. As proof of this, the 22 subjects selected for the Smoke Check-meter assay showed satisfactory values (Fig. 4).

#### 4. Discussion

The clinical observations highlighted in this research work were aimed to assess the improvements of periodontal health in smokers that switched to e-cigarettes. A clinical approach was used for the evaluation of general health status and, more in detail, of oral health status.

Systemic diseases induced by tobacco smoking are well known and widely documented in the scientific literature.<sup>[27-31]</sup> Furthermore, several studies assess that tobacco smoking entails an overall increase of the risk to develop severe periodontal diseases.<sup>[32]</sup>

Our observations revealed an interesting growing trend, relating to PI, BI, and PBI in the 110 subjects considered in this study. To our knowledge, there are no data in literature related to the variations of such periodontal indexes in subjects that dropped the tobacco cigarette, and started to use the e-cigarette instead.

We observed a constant reduction of bacterial plaque on teeth surfaces, from baseline at  $T_0$  to the end of the observational period at  $T_2$ . More precisely, subjects of group 1 showed a homogeneous presence of a thin film of plaque at  $T_0$ , which visibly decreased toward  $T_1$  until it completely disappeared in all



**Figure 4.** Composite figure. On the left is represented the table reporting the "Smoke Check-meter" values, related to 22 out of 110 randomly selected patients: values are indicated with a color according to the colorimetric scale, briefly reported on the right part of the figure in a separate table. The colorimetric scale is aimed to assess the estimated smoke consumption; in this light, it should represent an index of the reliability of the study. Starting from the null hypothesis each patient has stopped his smoke consumption at the start of this study, it is useful to understand that the green and yellow colors are the desirable values because they are indicative of absence/limited presence of CO in the patient's breathing. The histogram describes the numerosity of patients classified as VLS and LS, according to the amount of CO detected by "Smoke Check-meter." CO=carbon monoxide, LS=light smokers, VLS=very light smokers.

subjects of group 1 at T<sub>2</sub>. Interestingly, this result was more marked in subjects of group 2 characterized by a huge presence of plaque at T<sub>0</sub>.

Epidemiological studies have clearly demonstrated that tobacco smokers have a worse oral hygiene than nonsmokers<sup>[33]</sup>. There are some evidences that smoking habit increases the mineralizing potential of saliva.<sup>[34]</sup> Moreover, recent studies have demonstrated that the plaque quantity, the plaque architecture, and its bacterial composition are rather similar between smokers and nonsmokers patients; instead, smokers show a nicotine-related vasoconstriction of the gingival tissue,<sup>[33]</sup> leading to a slight decrease of the crevicular fluid flow: such flow reduction is able to impair the immunological reply to bacterial growth on dental tissues; moreover, the gingival vasoconstriction inhibits the early signs of gingivitis. In conclusion, since PI is mainly related to plaque control and to a proper flow of crevicular fluid, and since heavy smokers were found to have worse oral hygiene and worse crevicular fluid flow than nonsmokers: the PI variation, reported in this study, could be related to the difference in the crevicular fluid flow and to the different ability of e-smokers to manage their oral hygiene.

Appreciable improvements were likewise observed for gingival bleeding. Although there might be some controversy regarding the effect of tobacco consumption on the gingival vasculature, there is a clear clinical evidence that nicotine induces vasoconstriction of peripheral blood vessels, thus reducing bleeding.<sup>[33]</sup>

On the other hand, as shown in literature, nicotine represents a contributing cause to periodontal degradation by affecting the fibroblasts attachment ability,<sup>[35,36]</sup> collagen production, and integrin production.<sup>[37,38]</sup> Moreover, nicotine increases the amount of proinflammatory cytokines in cultured gingival keratinocytes and fibroblasts.<sup>[39,40]</sup>

The results observed in our study could be explained by the fact that the combined harmful effects of tobacco and nicotine on periodontal health<sup>[41]</sup> are now limited only to the amount of nicotine in the e-cigarettes thus contributing to the reduction of the typical side effects of smoking habit, and of the severity of smoke-related oral diseases.

In our study, we analyzed for the first time the changes of the status of periodontal health in individuals who have dropped the common cigarette and started to use e-cigarette.

A first relevant take-home message deriving from our observational/clinical study is that many subjects showed a reduction of the need to smoke combustible cigarettes, even if this only a limited pilot study that must be enlarged and confirmed by other more numerous RCTs. This major result has a high relevance as it implies the reduction of the addiction to the chemical component of the combustible cigarettes, and to the psycho-social aspect that characterizes the typical smoker.

Nevertheless, although e-cigarette represents a valuable alternative to traditional cigarettes, thus a concrete aid for all the smokers needing to quit smoking; however, many respectable studies suggested that the main components of e-cigarette liquids could be potentially harmful, because of the still poorly known effects of such substances on the human organism.<sup>[42]</sup>

In our role of highly experienced physicians in the field of oral medicine, we want to highlight how the switching from combustible to e-cigarette can represent a valid support toward a clear improvement in some specific oral health parameters, leading also to overall benefits toward patients' wellbeing.

## Acknowledgments

The Authors thank Department of Oral Hygiene and Periodontics of Calabro dental Clinic for the collaboration in this research work.

## References

- [1] Leung CM, Leung AK, Hon KL, et al. Fighting tobacco smoking—a difficult but not impossible battle. *Int J Environ Res Public Health* 2009;6:69–83.
- [2] Storr CL, Cheng H, Alonso J, et al. Smoking estimates from around the world: data from the first 17 participating countries in the World Mental Health Survey Consortium. *Tob Control* 2010;19:65–74.
- [3] Tweed JO, Hsia SH, Lutfy K, et al. The endocrine effects of nicotine and cigarette smoke. *Trends Endocrinol Metab* 2012;23:334–42.
- [4] Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2010;122:e584–636.
- [5] Rendu F, Peoc'h K, Berlin I, et al. Smoking related diseases: the central role of monoamine oxidase. *Int J Environ Res Public Health* 2011;8:136–47.
- [6] Wald NJ, Hackshaw AK. Cigarette smoking: an epidemiological overview. *Br Med Bull* 1996;52:3–11.
- [7] Lippi G, Favaloro EJ, Meschi T, et al. E-cigarettes and cardiovascular risk: beyond science and mysticism. *Semin Thromb Hemost* 2014;40:60–5.
- [8] Hull MG, North K, Taylor H, et al. Delayed conception and active and passive smoking. The Avon Longitudinal Study of Pregnancy and Childhood Study Team. *Fertil Steril* 2000;74:725–33.
- [9] Wright KP, Trimarchi JR, Allsworth J, et al. The effect of female tobacco smoking on IVF outcomes. *Hum Reprod* 2006;21:2930–4.
- [10] Dautzenberg B. Tobacco-related diseases. *Rev Prat* 2004;54:1877–82.
- [11] Williams SA, Kwan SY, Parsons S. Parental smoking practices and caries experience in pre-school children. *Caries Res* 2000;34:117–22.
- [12] Mondal P, Datta S, Maiti GP, et al. Comprehensive SNP scan of DNA repair and DNA damage response genes reveal multiple susceptibility loci conferring risk to tobacco associated leukoplakia and oral cancer. *PLoS One* 2013;8:e56952.
- [13] Vellappally S, Fiala Z, Smejkalova J, et al. Smoking related systemic and oral diseases. *Acta Medica (Hradec Kralove)* 2007;50:161–6.
- [14] Chiu CT, Li CF, Li JR, et al. Candida invasion and influences in smoking patients with multiple oral leucoplakias – a retrospective study. *Mycoses* 2011;54:e377–83.
- [15] Javed F, Bashir Ahmed H, Romanos GE. Association between environmental tobacco smoke and periodontal disease: a systematic review. *Environ Res* 2014;133:117–22.
- [16] Razali M, Palmer RM, Coward P, et al. A retrospective study of periodontal disease severity in smokers and non-smokers. *Br Dent J* 2005;198:495–8. discussion 485.
- [17] Muller HP, Stadermann S, Heinecke A. Gingival recession in smokers and non-smokers with minimal periodontal disease. *J Clin Periodontol* 2002;29:129–36.
- [18] Silva CO, Ribeiro Edel P, Sallum AW, et al. Free gingival grafts: graft shrinkage and donor-site healing in smokers and non-smokers. *J Periodontol* 2010;81:692–701.
- [19] Sanchez-Perez A, Moya-Villaescusa MJ, Caffesse RG. Tobacco as a risk factor for survival of dental implants. *J Periodontol* 2007;78:351–9.
- [20] Tashkin DP, Murray RP. Smoking cessation in chronic obstructive pulmonary disease. *Respir Med* 2009;103:963–74.
- [21] Hecht SS. Cigarette smoking: cancer risks, carcinogens, and mechanisms. *Langenbecks Arch Surg* 2006;391:603–13.
- [22] Etter JF, Zather E, Svensson S. Analysis of refill liquids for electronic cigarettes. *Addiction* 2013;108:1671–9.
- [23] Grana R, Benowitz N, Glantz SA. E-cigarettes: a scientific review. *Circulation* 2014;129:1972–86.
- [24] Etter JF, Bullen C, Flourié AD, et al. Electronic nicotine delivery systems: a research agenda. *Tob Control* 2011;20:243–8.
- [25] Cobb NK, Abrams DB. E-cigarette or drug-delivery device? Regulating novel nicotine products. *N Engl J Med* 2011;365:193–5.
- [26] Goniewicz ML, Knysak J, Gawron M, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. *Tob Control* 2014;23:133–9.
- [27] Polosa R, Rodu B, Caponnetto P, et al. A fresh look at tobacco harm reduction: the case for the electronic cigarette. *Harm Reduct J* 2013;10:19.
- [28] Feil PH, Grauer JS, Gadbury-Amyot CC, et al. Intentional use of the Hawthorne effect to improve oral hygiene compliance in orthodontic patients. *J Dent Educ* 2002;66:1129–35.
- [29] Musk AW, de Klerk NH. History of tobacco and health. *Respirology* 2003;8:286–90.
- [30] Doll R. Uncovering the effects of smoking: historical perspective. *Stat Methods Med Res* 1998;7:87–117.
- [31] Hoffmann D, Hoffmann I. The changing cigarette 1950–1995. *J Toxicol Environ Health* 1997;50:307–64.
- [32] Whelton H, Kingston R, O'Mullane D, et al. Randomized controlled trial to evaluate tooth stain reduction with nicotine replacement gum during a smoking cessation program. *BMC Oral Health* 2012;12:13.
- [33] Pejić AOR, Kesić L, Kojović D. Smoking and periodontal disease a review. *Med Biol* 2007;14:7.
- [34] Erdemir EO, Erdemir A. The detection of salivary minerals in smokers and non-smokers with chronic periodontitis by the inductively coupled plasma-atomic emission spectrophotometry technique. *J Periodontol* 2006;77:990–5.
- [35] Tanur E, McQuade MJ, McPherson JC, et al. Effects of nicotine on the strength of attachment of gingival fibroblasts to glass and non-diseased human root surfaces. *J Periodontol* 2000;71:717–22.
- [36] Raulin LA, McPherson JC3rd, McQuade MJ, et al. The effect of nicotine on the attachment of human fibroblasts to glass and human root surfaces in vitro. *J Periodontol* 1988;59:318–25.
- [37] Tipton DA, Dabbous MK. Effects of nicotine on proliferation and extracellular matrix production of human gingival fibroblasts in vitro. *J Periodontol* 1995;66:1056–64.
- [38] Austin GW, Cuenin MF, Hokett SD, et al. Effect of nicotine on fibroblast beta 1 integrin expression and distribution in vitro. *J Periodontol* 2001;72:438–44.
- [39] Johnson GK, Organ CC. Prostaglandin E2 and interleukin-1 concentrations in nicotine-exposed oral keratinocyte cultures. *J Periodontal Res* 1997;32:447–54.
- [40] Wendell KJ, Stein SH. Regulation of cytokine production in human gingival fibroblasts following treatment with nicotine and lipopolysaccharide. *J Periodontol* 2001;72:1038–44.
- [41] Malhotra R, Kapoor A, Grover V, et al. Nicotine and periodontal tissues. *J Indian Soc Periodontol* 2010;14:72–9.
- [42] Willershausen I, Wolf T, Weyer V, et al. Influence of E-smoking liquids on human periodontal ligament fibroblasts. *Head Face Med* 2014;10:39.